Collegium Pharmaceutical, Inc.
DE ˙ DB ˙ US19459J1043
26,00 € ↓ -0,80 (-2,99%)
2026-06-03
AKTIENPREIS
SecurityDE:354 / Collegium Pharmaceutical, Inc.
InstitutionFranklin Resources Inc
Latest Disclosed Ownership1,255,371 shares
Ownership 3.60%
Franklin Resources Inc ownership in 354 / Collegium Pharmaceutical, Inc.

2021-02-01 - Franklin Resources Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,255,371 shares of Collegium Pharmaceutical, Inc. (DE:354). This represents 3.6 percent ownership of the company. In their previous filing dated 2020-02-04 , Franklin Resources Inc had reported owning 1,770,152 shares, indicating a decrease of -29.08 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2021-02-01 2021-02-01 13G/A 1,770,152 1,255,371 -29.08 3.60 -32.08
2020-02-04 2020-02-04 13G/A 1,834,289 1,770,152 -3.50 5.30 -3.64
2019-01-25 2019-01-25 13G 1,511,775 1,834,289 21.33 5.50 19.57
2018-02-06 2018-02-06 13G/A 1,797,902 1,511,775 -15.91 4.60 -26.98
2017-02-07 2017-02-07 13G 1,797,902 6.30

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 174,362 136,598 361.71 5,766 229.86 0.0002
2026-02-11 2025-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 37,764 6,852 22.17 1,748 61.70 0.0004
2025-11-13 2025-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 30,912 1,740 5.96 1,082 25.41 0.0003
2025-08-12 2025-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 29,172 409 1.42 863 0.47 0.0002
2025-05-13 2025-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 28,763 -1,717 -5.63 859 -1.72 0.0002
2025-02-12 2024-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 30,480 -145 -0.47 873 -24.94 0.0002
2024-11-27 2024-09-30 13F/A-1 COLLEGIUM PHARMACEUTICAL COM 19459J104 30,625 3,620 13.40 1,164 33.83 0.0003
2024-11-12 2024-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 30,625 3,620 1,164 0.0001
2024-08-14 2024-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 27,005 1,998 7.99 870 -10.41 0.0003
2024-05-13 2024-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 25,007 629 2.58 971 29.33 0.0003
2024-02-09 2023-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 24,378 1,577 6.92 750 47.35 0.0004
2023-11-13 2023-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 22,801 4,357 23.62 510 28.54 0.0003
2023-08-11 2023-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 18,444 18,444 396 0.0002
2021-05-13 2021-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 0 -1,255,371 -100.00 0 -100.00
2021-02-10 2020-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,255,371 -410,501 -24.64 25,145 -27.50 0.0106
2020-11-12 2020-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,665,872 1,209 0.07 34,684 19.19 0.0168
2020-08-13 2020-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,664,663 -165,109 -9.02 29,099 -2.62 0.0150
2020-05-13 2020-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,829,772 59,620 3.37 29,881 -17.97 0.0199
2020-03-11 2019-12-31 13F/A-1 COLLEGIUM PHARMACEUTICAL COM 19459J104 1,770,152 -92,819 -4.98 36,429 70.33 0.0191
2020-02-12 2019-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,770,152 -92,819 36,429 4,601.4814
2019-11-14 2019-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,862,971 7,126 0.38 21,387 -12.36 0.0116
2019-08-14 2019-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,855,845 22,007 1.20 24,404 -12.10 0.0130
2019-05-15 2019-03-31 13F/A-1 COLLEGIUM PHARMACEUTICAL COM 19459J104 1,833,838 -451 -0.02 27,764 -11.85 0.0149
2019-05-14 2019-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,833,838 -451 27,764
2019-02-12 2018-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,834,289 74,783 4.25 31,495 21.44 0.0190
2018-11-13 2018-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,759,506 347,064 24.57 25,935 -23.01 0.0129
2018-08-14 2018-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,412,442 -56,677 -3.86 33,686 -10.25 0.0173
2018-05-10 2018-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,469,119 -42,656 -2.82 37,535 34.50 0.0190
2018-02-14 2017-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,511,775 -721,372 -32.30 27,907 19.13 0.0134
2017-11-13 2017-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 2,233,147 29,366 1.33 23,426 -15.03 0.0115
2017-08-10 2017-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 2,203,781 -27,422 -1.23 27,569 22.82 0.0137
2017-05-12 2017-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 2,231,203 433,301 24.10 22,446 -19.82 0.0114
2017-02-14 2016-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 1,797,902 890,868 98.22 27,994 60.25 0.0145
2016-11-14 2016-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 907,034 3,432 0.38 17,469 63.14 0.0091
2016-08-11 2016-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 903,602 74,003 8.92 10,708 -28.88 0.0058
2016-05-10 2016-03-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 829,599 505,299 155.81 15,057 68.82 0.0080
2016-04-27 2015-12-31 13F/A-1 COLLEGIUM PHARMACEUTICAL COM 19459J104 324,300 -11,000 -3.28 8,919 20.32 0.0045
2016-02-12 2015-12-31 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 324,300 8,919
2015-11-10 2015-09-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 335,300 4,700 1.42 7,413 25.69 0.0037
2015-08-12 2015-06-30 13F COLLEGIUM PHARMACEUTICAL COM 19459J104 330,600 330,600 5,898 0.0027
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.